## **Publishing Neural Networks in Drug Discovery Might Compromise Training Data Privacy**



User

Adversary

Fabian Krüger<sup>1,2,3</sup>, Johan Östman<sup>4</sup>, Lewis Mervin<sup>1</sup>, Igor Tetko<sup>3</sup>, Ola Engkvist<sup>1,5</sup>

AstraZeneca R&D1, Technical University of Munich2, Helmholtz Munich3, Al Sweden4, Chalmers University of Technology5

#### **Abstract**

This study investigates the risks of exposing confidential chemical structures when machine learning models trained on these structures are made publicly available. We use membership inference attacks, a common method to assess privacy that is largely unexplored in the context of drug discovery, to examine neural networks for molecular property prediction in a black-box setting. Our results reveal significant privacy risks across all evaluated datasets and neural network architectures.

#### Introduction

- Datasets in drug discovery are expensive to generate. Leaking information about proprietary data can severely harm an organization.
- Organizations need to balance benefits from open science and collaboration with the scientific community with their privacy concerns.
- There is a lack of studies on how much training data information an be inferred from neural networks in a drug discovery context.

#### **Conclusions**

- It is consistently possible to identify parts of the training data, even at false positive rates as low as 0 (under some assumptions).
- Combining both attacks allows getting even more information about the training data.
- Minority class molecules are easier to identify.
- Message passing neural network has the least information leakage.

### Paper:



#### References

- Membership inference attacks from first principles, Carlini et al., IEEE, 2022.
- Low-cost high-power membership inference attacks,
   Zarifzadeh et al., ICML 2024
- A bayesian approach to in silico blood-brain barrier penetration modeling,
- Martins et al., JCIM, 2012

  4. Benchmark data set for in silico prediction of ames mutagenicity.
- Hansen et al., JCIM, 2009
- Machine learning on dna-encoded library count data using an uncertainty-aware probabilistic loss function, Lim et al., JCIM 2022
- Hergcentral: a large database to store, retrieve, and analyze compound-human ether-a-go-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development,

Du et al., Assay and drug development technologies, 2011

# +--- Q +---

#### **Methods**


 Developed and evaluated neural networks trained on diverse molecular representations (fingerprints, graphs, SMILES) across four drug discovery datasets.

Confidential

**Training** 


data

 Applied state-of-the-art membership inference attacks (LiRA¹ and RMIA²) in a black-box setting to measure how well attackers can identify molecules from training data.



Neural network

#### Results



True positive rates for identifying training data molecules at a false positive rate of 0. The distributions of 20 experimental repetitions are shown for each representation and dataset, for both the likelihood ratio attack (LiRA¹) and the robust membership inference attack (RMIA²). Distributions with significantly higher true positive rates (information leakage) than the baseline (random guessing) are indicated by red stars. Training dataset sizes are: 859 molecules for the blood-brain barrier permeability dataset ³; 3,264 for the Ames mutagenicity prediction dataset ⁴; 48,837 for the DNA-encoded library enrichment dataset ⁵; and 137,853 for the hERG channel inhibition dataset ⁶.

#### Acknowledgements